120 related articles for article (PubMed ID: 32327298)
1. Evaluating Family History Links between Breast Cancer and Prostate Cancer Among PLCO Trial Participants.
Abdel-Rahman O
Clin Breast Cancer; 2020 Aug; 20(4):300-306. PubMed ID: 32327298
[TBL] [Abstract][Full Text] [Related]
2. Prostate Cancer Incidence and Mortality in Relationship to Family History of Prostate Cancer; Findings From The PLCO Trial.
Abdel-Rahman O
Clin Genitourin Cancer; 2019 Aug; 17(4):e837-e844. PubMed ID: 31213414
[TBL] [Abstract][Full Text] [Related]
3. Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials.
Tsodikov A; Gulati R; Heijnsdijk EAM; Pinsky PF; Moss SM; Qiu S; de Carvalho TM; Hugosson J; Berg CD; Auvinen A; Andriole GL; Roobol MJ; Crawford ED; Nelen V; Kwiatkowski M; Zappa M; Luján M; Villers A; Feuer EJ; de Koning HJ; Mariotto AB; Etzioni R
Ann Intern Med; 2017 Oct; 167(7):449-455. PubMed ID: 28869989
[TBL] [Abstract][Full Text] [Related]
4. Assessing contamination and compliance in the prostate component of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.
Pinsky PF; Blacka A; Kramer BS; Miller A; Prorok PC; Berg C
Clin Trials; 2010 Aug; 7(4):303-11. PubMed ID: 20571134
[TBL] [Abstract][Full Text] [Related]
5. Lung cancer incidence and mortality in relationship to hormone replacement therapy use among women participating in the PLCO trial: a post hoc analysis.
Abdel-Rahman O
Int J Clin Oncol; 2020 May; 25(5):885-891. PubMed ID: 31919692
[TBL] [Abstract][Full Text] [Related]
6. Association of Nonadherence to Cancer Screening Examinations With Mortality From Unrelated Causes: A Secondary Analysis of the PLCO Cancer Screening Trial.
Pierre-Victor D; Pinsky PF
JAMA Intern Med; 2019 Feb; 179(2):196-203. PubMed ID: 30592477
[TBL] [Abstract][Full Text] [Related]
7. Breast cancer epidemiology according to recognized breast cancer risk factors in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial Cohort.
Lacey JV; Kreimer AR; Buys SS; Marcus PM; Chang SC; Leitzmann MF; Hoover RN; Prorok PC; Berg CD; Hartge P;
BMC Cancer; 2009 Mar; 9():84. PubMed ID: 19292893
[TBL] [Abstract][Full Text] [Related]
8. Vasectomy and Risk of Prostate Cancer in a Screening Trial.
Shoag J; Savenkov O; Christos PJ; Mittal S; Halpern JA; Askin G; Shoag D; Golan R; Lee DJ; O'Malley P; Najari B; Eisner B; Hu JC; Scherr D; Schlegel P; Barbieri CE
Cancer Epidemiol Biomarkers Prev; 2017 Nov; 26(11):1653-1659. PubMed ID: 28830873
[No Abstract] [Full Text] [Related]
9. Renal-cell carcinoma risk estimates based on participants in the prostate, lung, colorectal, and ovarian cancer screening trial and national lung screening trial.
Lotan Y; Karam JA; Shariat SF; Gupta A; Roupret M; Bensalah K; Margulis V
Urol Oncol; 2016 Apr; 34(4):167.e9-16. PubMed ID: 26602092
[TBL] [Abstract][Full Text] [Related]
10. Clinically relevant changes in family history of cancer over time.
Ziogas A; Horick NK; Kinney AY; Lowery JT; Domchek SM; Isaacs C; Griffin CA; Moorman PG; Edwards KL; Hill DA; Berg JS; Tomlinson GE; Anton-Culver H; Strong LC; Kasten CH; Finkelstein DM; Plon SE
JAMA; 2011 Jul; 306(2):172-8. PubMed ID: 21750294
[TBL] [Abstract][Full Text] [Related]
11. Prostate-Specific Antigen (PSA)-Based Population Screening for Prostate Cancer: An Evidence-Based Analysis.
Pron G
Ont Health Technol Assess Ser; 2015; 15(10):1-64. PubMed ID: 26366236
[TBL] [Abstract][Full Text] [Related]
12. Prevalence of family history of breast, colorectal, prostate, and lung cancer in a population-based study.
Mai PL; Wideroff L; Greene MH; Graubard BI
Public Health Genomics; 2010; 13(7-8):495-503. PubMed ID: 20389042
[TBL] [Abstract][Full Text] [Related]
13. Familial clustering of breast and prostate cancer and risk of postmenopausal breast cancer in the Women's Health Initiative Study.
Beebe-Dimmer JL; Yee C; Cote ML; Petrucelli N; Palmer N; Bock C; Lane D; Agalliu I; Stefanick ML; Simon MS
Cancer; 2015 Apr; 121(8):1265-72. PubMed ID: 25754547
[TBL] [Abstract][Full Text] [Related]
14. Variation of colorectal, breast and prostate cancer screening activity in Switzerland: Influence of insurance, policy and guidelines.
Ulyte A; Wei W; Dressel H; Gruebner O; von Wyl V; Bähler C; Blozik E; Brüngger B; Schwenkglenks M
PLoS One; 2020; 15(4):e0231409. PubMed ID: 32298325
[TBL] [Abstract][Full Text] [Related]
15. First-degree family history of breast cancer is associated with prostate cancer risk: a systematic review and meta-analysis.
Ren ZJ; Cao DH; Zhang Q; Ren PW; Liu LR; Wei Q; Wei WR; Dong Q
BMC Cancer; 2019 Sep; 19(1):871. PubMed ID: 31477094
[TBL] [Abstract][Full Text] [Related]
16. Confirmation of family cancer history reported in a population-based survey.
Mai PL; Garceau AO; Graubard BI; Dunn M; McNeel TS; Gonsalves L; Gail MH; Greene MH; Willis GB; Wideroff L
J Natl Cancer Inst; 2011 May; 103(10):788-97. PubMed ID: 21562245
[TBL] [Abstract][Full Text] [Related]
17. Lower TSH and higher free thyroxine predict incidence of prostate but not breast, colorectal or lung cancer.
Chan YX; Knuiman MW; Divitini ML; Brown SJ; Walsh J; Yeap BB
Eur J Endocrinol; 2017 Oct; 177(4):297-308. PubMed ID: 28684452
[TBL] [Abstract][Full Text] [Related]
18. The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial of the National Cancer Institute: history, organization, and status.
Gohagan JK; Prorok PC; Hayes RB; Kramer BS;
Control Clin Trials; 2000 Dec; 21(6 Suppl):251S-272S. PubMed ID: 11189683
[TBL] [Abstract][Full Text] [Related]
19. Implications of false-positive results for future cancer screenings.
Taksler GB; Keating NL; Rothberg MB
Cancer; 2018 Jun; 124(11):2390-2398. PubMed ID: 29682740
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
